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dn Association Analysis of Murine Anxiety Genes in
umans Implicates Novel Candidate Genes for
nxiety Disorders
onas Donner, Sami Pirkola, Kaisa Silander, Laura Kananen, Joseph D. Terwilliger, Jouko Lönnqvist,
eena Peltonen, and Iiris Hovatta
ackground: Human anxiety disorders are complex diseases with largely unknown etiology. We have taken a cross-species approach to
dentifygenes that regulate anxiety-likebehaviorwith inbredmouse strains thatdiffer in their innateanxiety levels as amodel.Wepreviously
dentified17geneswith expression levels that correlatewith anxietybehavior across the studied strains. In thepresent study,we tested their
3 known human homologues as candidate genes for human anxiety disorders with a genetic association study.
ethods: We describe an anxiety disorder study sample derived from a Finnish population-based cohort and consisting of 321 patients
nd 653 carefully matched control subjects, all interviewed to obtain DSM-IV diagnoses. We genotyped altogether 208 single nucleotide
olymorphisms (SNPs) (all non-synonymous SNPs, SNPs that alter potential microRNA binding sites, and gap-filling SNPs selected on the
asis of HapMap information) from the investigated anxiety candidate genes.
esults: Specific alleles and haplotypes of six of the examined genes revealed some evidence for association (p .01). Themost significant
vidence for association with different anxiety disorder subtypes were: p  .0009 with ALAD (-aminolevulinate dehydratase) in social
hobia, p .009 with DYNLL2 (dynein light chain 2) in generalized anxiety disorder, and p .004 with PSAP (prosaposin) in panic disorder.
onclusions: Our findings suggest that variants in these genes might predispose to specific human anxiety disorders. These results
llustrate the potential utility of cross-species approaches in identification of candidate genes for psychiatric disorders.eyWords:Anxietydisorders, associationstudy,genetic isolate, SNP
ear and anxiety are normal emotional responses to threat-
ening situations. However, when exaggerated and causing
distress, disability, and loss of quality of life, they manifest
s anxiety disorders as classified in the DSM-IV (1) and ICD-10
2). In DSM-IV, anxiety disorders include panic disorder (with or
ithout agoraphobia), obsessive-compulsive disorder, general-
zed anxiety disorder, post-traumatic stress disorder, social pho-
ia, agoraphobia, and specific phobias. The combined lifetime
revalence of these disorders in the general population has been
stimated to be 16.6% on average (3). Anxiety disorders are also
ighly comorbid with each other and other psychiatric disorders
uch as depression and substance abuse (4).
Anxiety disorders are complex diseases, influenced by a
ombination of both genetic and environmental predisposing
actors. For example, the heritability of panic disorder and
eneralized anxiety disorder has been estimated to be 48% and 32%,
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oi:10.1016/j.biopsych.2008.06.002respectively (5). Models suggest that the genetic architecture of
anxiety disorders can be best explained by one shared set of genetic
factors mainly influencing predisposition to panic disorder, gener-
alized anxiety disorder, and agoraphobia and another set primarily
underlying specific phobias (6). Furthermore, there is evidence for
considerable overlap between the genetic factors influencing anxi-
ety disorders and those influencing depression and the personality
traits neuroticism and introversion (7,8).
Because the pursuit of human anxiety disorder susceptibil-
ity genes by conventional linkage and association mapping
has proved to be demanding (reviewed in 9), there is a need
to consider the aid of alternative approaches, such as ones
relying on animal models for identification of genes and loci
with relevance for complex traits (reviewed in 9,10). Several
paradigms for the measurement of anxiety in mice have been
developed and pharmacologically validated, and they are
considered to model aspects of human anxiety (e.g., 11–13).
We have previously combined behavioral testing with gene
expression profiling of specific brain regions to identify genes
whose expression levels might regulate anxiety-related behav-
ior in mice (14). This approach takes advantage of the
different innate levels of anxiety-like behavior of well-charac-
terized inbred mouse strains. Briefly, by combining behavioral
analysis of six inbred strains with gene expression profiling of
seven brain regions involved in the regulation of anxiety, we
identified 17 genes with expression levels that correlated
significantly with the anxiety phenotype across all strains in at
least one brain region. We further showed functionally that 2
of the identified genes, glyoxalase 1 (Glo1) and glutathione
reductase 1 (Gsr), regulate anxiety behavior in mice in vivo.
Although the 15 remaining genes were not tested functionally,
they remain strong candidate genes for anxiety. In the present
study, we tested these genes as candidate genes for human
anxiety disorders with a genetic association analysis in a
Finnish population-based study sample.
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tudy Sample
The individuals in this study derive from the Finnish popula-
ion-based Health 2000 Study carried out in 2000–2001. This
ork was approved by the institutional ethics committee of the
ational Public Health Institute, and written consent was ob-
ained. Identification of individuals with anxiety disorders has
een described in detail by Pirkola et al. (15,16). Briefly, the
2-month prevalence of DSM-IV mental disorders was estimated
rom a representative sample (n  6005) of the Finnish general
dult ( 30 years of age) population with the Composite
nternational Diagnostic Interview (CIDI). Finland represents a
ell-characterized genetic isolate (17), with approximately 2% of
ndividuals with foreign descent. No ethnic groups were ex-
luded during recruitment to obtain a representative epidemio-
ogical cohort, but the interview was conducted in Finnish,
xcluding all non-fluent foreigners. A computer-aided version of
he mental health interview (M-CIDI) was administered by
rained non-psychiatric healthcare professionals and designed to
etermine the 12-month prevalence of a set of clinically and
pidemiologically relevant mental disorders. These included
ajor depressive disorder, dysthymia, generalized anxiety disor-
er, panic disorder with or without agoraphobia, agoraphobia,
ocial phobia, and alcohol abuse and dependence. The total
umber of reliably performed mental health interviews was 6005,
mounting to 75% of the original sample. Compared with CIDI
articipants, the dropouts (n 981) had somewhat higher scores
n the Beck Depression Inventory (BDI), indicating depressive
ymptoms, and General Health Questionnaire-12 (GHQ-12),
ndicating psychic distress. They also had slightly older age,
ower education, and were more frequently single. Although this
ight bias the final results toward underestimation of prevalence
f mental disorders in the general population, we believe that the
ost common anxiety disorders are well-represented in our
ohort. Due to the structure of the interview, we were not able to
eliably diagnose obsessive-compulsive disorder and post-trau-
atic stress disorder and chose to focus on a subset of the most
linically relevant anxiety disorders in the Finnish population.
From this cohort, we initially selected all individuals with a
SM-IV anxiety disorder diagnosis for analysis (core diagnostic
roup). In addition, we broadened our definition of anxiety
isorder subjects to include individuals with sub-threshold diag-
oses as defined by the CIDI (extended diagnostic group). For
ach case, we selected two control subjects who lacked diag-
osed anxiety or major mental disorders and were matched
ccording to gender, age ( 1 year), and hospital catchment
rea. The DNA was not available from 34 subjects (15 cases and
able 1. Demographic Characteristics of the Health 2000 Anxiety Disorder
iagnostic Group
DSM-IV
Casesa
DSM-IV
Sub-Threshold Cases
anic Disorderc 108 0
eneralized Anxiety Disorder 73 30
ocial Phobia 58 7
goraphobia 31 15
hobia, not otherwise specified 58 0
ll Studied Anxiety Disorders 282 39
aCore diagnostic group.
bExtended diagnostic group.
cIncludes both panic disorder with and without agoraphobia.9 control subjects), and therefore, the final analyzed studysample consisted of 321 cases and 653 control subjects (Table 1).
Forty-one core subjects were diagnosed with more than one
anxiety disorder (5 with three disorders, and 36 with two
disorders). The most frequent combination of diagnoses was
panic disorder comorbidity with social phobia (18 subjects).
Single Nucleotide Polymorphism Selection
The association study was carried out in two stages. In stage
I, we examined the known human homologues of 13 anxiety
candidate genes identified in the mouse (14) with a set of 139
carefully selected single nucleotide polymorphisms (SNPs; Table
2). In stage II, we followed up on positive findings by genotyping
69 additional markers from genes showing evidence for associ-
ation after stage I. The 208 markers selected for genotyping
represented three different variation groups: non-synonymous
SNPs, haplotype-tagging SNPs, and putative polymorphic mi-
croRNA (miRNA) binding sites.
First, we selected all known validated and unvalidated non-
synonymous SNPs with SNPper (18; http://snpper.chip.org),
with the aim to identify SNPs that potentially alter the function of
the gene products. Second, we retrieved HapMap (19; http://
www.hapmap.org) phase I genotype information for the
European-derived Caucasian/European ancestry (CEU) popula-
tion and used the Tagger algorithm as implemented in Haplov-
iew (20; http://www.broad.mit.edu/mpg/haploview) to identify
complementary tagSNPs for genotyping. TagSNPs were required
to have minor allele frequencies  .05, when possible and to
capture the variation of other SNPs with minor allele frequen-
cies  .05 by a minimum r2  .8. For 11 genes, we selected
tagging SNPs every 5 kb, on average. For the two largest genes,
CDH2 and EPB41L4A, we selected one tagging SNP/exon. In
stage II of the study, we selected supplementary tagSNPs with
HapMap phase II data. Third, to select SNPs that potentially
alter gene expression, we used the Patrocles database (http://
www.patrocles.org) to identify validated and unvalidated
SNPs resulting in putative polymorphic miRNA binding sites
within the 3’-untranslated regions (UTRs) of our candidate
genes and genotyped them in stage II.
Genotyping and Quality Control
The DNA was extracted from whole blood at the DNA
extraction core facility of the National Public Health Institute with
the Puregene manual DNA extraction kit (Gentra Systems, Min-
neapolis, Minnesota). The DNA quality control (QC) measures
consisted of gender-specific polymerase chain reaction to verify
that observed gender matched database information and geno-
typing of five polymorphic microsatellites to verify that samples
y Sample
Controls Total Men Women
Mean
Age SD
218 326 106 (32.5%) 220 (67.5%) 46.7 11.3
206 309 122 (39.5%) 187 (60.5%) 50.6 12.6
133 198 99 (50.0%) 99 (50.0%) 45.4  10.2
94 140 60 (42.9%) 80 (57.1%) 52.8 13.0
121 179 54 (30.2%) 125 (69.8%) 54.6 13.3
653 974 357 (36.7%) 617 (63.3%) 49.8 12.7Stud
Cases
Totalb
108
103
65
46
58
321were not contaminated (21).
www.sobp.org/journal
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wGenotyping was done with Sequenom MassARRAY genotyp-
ng technology (Sequenom, San Diego, California) with iPLEX
hemistry in stage I and iPLEX Gold chemistry in stage II. Assay
onditions were as recommended by the manufacturer, and
ssay information including primer sequences is available from
he authors upon request. Genotyping QC measures consisted of
hecking no-template control samples for allele peaks; reviewing
ll marker data and verifying that genotype clusters were well
istinguished and outliers removed; verifying consistencies in
enotype calls of randomly selected duplicate samples (approx-
mately 2% of samples across, and 2% of samples within sample
lates); disregarding marker assays with low success rates
 85%); and discarding all genotype information for individual
amples with genotype calls for  75% of the analyzed markers.
urthermore, Hardy-Weinberg equilibrium was evaluated for
ach marker in the control sample with a 2 test in addition to
onfirming Mendelian inheritance of marker alleles by genotyp-
ng an additional sample of 60 anonymous parent-offspring trios.
tatistical Analysis
We estimated the magnitude of genotypic relative risk possi-
le to detect with the studied sample size (321 cases and 653
ontrol subjects) with the Genetic Power Calculator tool (22;
ttp://pngu.mgh.harvard.edu/purcell/gpc). Disease prevalence
as set at 5%, corresponding to the Finnish annual anxiety
isorder prevalence (15), inheritance to follow a dominant
odel, and the frequencies of disease and marker alleles were
efined as equal with D’  1. The simulation was run with a
ange of marker and disease allele frequencies (.01–.6) to
llustrate how they influence power to detect association.
Statistical analyses were carried out for core and extended
iagnostic groups for all anxiety disorders combined as well as
eparately for the subgroups panic disorder, generalized anxiety
isorder, and social phobia. Two subgroups, agoraphobia and
hobia not otherwise specified, were included in the analysis of
ll anxiety disorders combined but not analyzed separately due
o small sample size and phenotypic heterogeneity, respectively.
able 2. Investigated Candidate Genes and Number of Analyzed SNPs/Gen
ymbol
Gene Information
Name Position
LAD Aminolevulinate, -, dehydratase 9q33.1
DH2 Cadherin-2, type 1, N-cadherin (neuronal) 18q11.2
PSF4 Cleavage and polyadenylation specificity
factor 4, 30kDa
7q22.1
YNLL2 Dynein, light chain, LC8-type 2 17q22
PB41L4A Erythrocyte membrane protein band 4.1
like 4A
5q22.2
PHX1 Epoxide hydrolase 1, microsomal (xenobiotic) 1q42.1
LO1 Glyoxalase I 6p21.3-p21.1
SR Glutathione reductase 8p21.1
SAP Prosaposin (variant Gaucher disease and
metachromatic leukodystrophy)
10q21-q22
TGDS Prostaglandin D2 synthase 21kDa (brain) 9q34.2-q34.3
100A10 S100 calcium binding protein A10 1q21
CN1B Sodium channel, voltage-gated, type I, 	 19q13.1
LC15A2 Solute carrier family 15 (H
/peptide
transporter), member 2
3q13.33
otal
Number of genotyped single nucleotide polymorphisms (SNPs) that we
aPutative polymorphic microRNA (miRNA) binding sites selected with thA conventional 2  2 contingency table likelihood-ratio test
ww.sobp.org/journal(LRT) of independence of the SNP allele counts in cases and control
subjects (23), with p values determined from permutation testing,
was performed to test individual SNP alleles for association with
anxiety disorders. We analyzed 10,000 permutations of the dataset
to obtain empirical p values. In addition, we performed haplotype
analyses on 2- and 3-marker “sliding windows” with the
UNPHASED software (24; http://www.mrc-bsu.cam.ac.uk/person-
al/frank/software/unphased) that estimates haplotype frequencies
from unphased genotype data with an expectation-maximization
algorithm. Haplotypes were analyzed with the default full model
implemented by the software that tests the null hypothesis that there
is no difference in odds ratios between haplotypes using a likeli-
hood-ratio test. A zero frequency threshold of .01 was used to
exclude haplotypes with estimated frequencies below 1% in both
cases and control subjects. Empirical p values were calculated with
10 000 permutations.
To order the genes according to their significance with regard to
anxiety disorders, a supplementary analysis was performed to
examine whether significant trends in associations could be de-
tected across individual genes. The obtained pointwise p values for
all SNPs were ranked from most to least significant (1–1008), after
which they were divided into four classes representing the top and
bottom findings (top decile, second decile, second quintile, and
bottom 60%). For each gene, we then determined the distribution of
findings across these classes. A similar analysis was done in which
the p value for each of the 144 markers was minimized over all tests
performed to eliminate redundancy.
Results
Power Calculations
With marker and disease allele frequencies of 1%–60%, the
power calculations implied that our entire study sample would
provide  80% power to reject the null hypothesis of no
association at p  .05 when a genotypic relative risk was higher
than 1.48–2.62, with the exact value depending on the allele
Stage I Stage II
Total(kb) Non-Synonymous tagSNPs miRNA Sitesa tagSNPs
5.0 1 (1) 7 2 (3) 4 14 (4)
6.3 1 (2) 10 — 10 21 (2)
8.3 — 4 — — 4
6.0 — 4 — 2 (1) 6 (1)
6.7 3 10 (1) — 14 27 (1)
0.3 2 (5) 6 — — 8 (5)
7.2 1 (2) 6 - (1) 5 12 (3)
9.0 2 (6) 7 — 7 16 (6)
5.0 - (3) 9 1 (1) 5 15 (4)
4.2 - (3) 4 — 2 (1) 6 (4)
1.0 - (2) 3 — — 3 (2)
9.8 - (2) 3 — — 3 (2)
7.2 2 (3) 7 — — 9 (3)
12 (29) 80 (1) 3 (5) 49 (2) 144 (37)
nomorphic in our study sample is shown in parenthesis.
rocles database.e
Size
1
22
1
25
2
2
4
3
2
4frequency (Supplement 1).
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Out of the total 208 SNPs selected for genotyping, 181
arker assays (87%) met our QC criteria. Thirty-seven mark-
rs, typically unvalidated or rare non-synonymous polymor-
hisms or unvalidated putative polymorphic miRNA binding
ites, were monomorphic, making the total number of statis-
ically analyzed SNPs 144 (92 in stage I, and 52 in stage II;
able 2). The average genotyping success rate for the ana-
yzed markers was 98.7% (median 99.1%), and it varied from
6.1% (rs16933168) to 99.9% (13 markers). The average geno-
yping success rate in individual samples for the analyzed
arkers was 98.7% (median 100%), and it varied from 78.1% to
00%. Eight markers included in the analysis exhibited devi-
tion from Hardy-Weinberg equilibrium in the control sample
t p  .05, with the most significant p value being p  .015 for
arker rs16933168. Detailed results and allele frequencies for
ll analyzed markers are available in Supplement 2.
ssociation Analysis, Stage I
Statistical analysis of single-marker associations for 92 SNPs in
tage I identified markers from several genes exhibiting empirical
ointwise p values of  .05 (Supplement 2). The following
riteria were used to select genes for further investigation in stage
I: 1) at least two markers in the gene showing p  .05 in
llele-based association tests in any diagnostic group, or 2) a
aplotype window associated at p .05 in any diagnostic group.
n the basis of these criteria, eight genes were studied further:
LAD (-aminolevulinate dehydratase), CDH2 (cadherin 2; N-
adherin), DYNLL2 (dynein light chain 2), EPB41L4A (erythro-
yte membrane protein band 4.1 like 4a), GLO1 (glyoxalase I),
SR (glutathione reductase), PSAP (prosaposin), and PTGDS
prostaglandin D2 synthase). We did not find any association
ith SNPs in CPSF4 (cleavage and polyadenylation specificity
actor 4), EPHX1 (epoxide hydrolase 1), S100A10 (s100 calcium
inding protein A10), SCN1B (voltage gated sodium channel,
ype I, 	), or SLC15A2 (solute carrier family 15 [H
/peptide
able 3. SNPs with p Value .01 in the LRT for Allelic Association
ene SNP rs # Alleles [A1/A2] Group
LAD rs818702 A/G Cases
Control
DH2 rs7240351b A/G Cases
Control
PB41L4A rs7719346 A/G Cases
Control
rs1464766 A/G Cases
Control
rs12657885b C/T Cases
Control
SAP rs4746097 C/T Cases
Control
rs11597008b C/T Cases
Control
TGDS rs4880179 A/G Cases
Control
Empirical p values from 10,000 permutations are shown. SNP, single n
eneralized anxiety disorder; PD, panic disorder; refer to Table 2 for gene n
aDSM-IV core diagnosis.
bRs-numbers of markers genotyped in stage II.
cDSM-IV extended diagnosis.transporter], member 2) genes and did not examine them further
after stage I.
Association Analysis, Stage II
Genotype data for 52 additional stage II SNPs was added to
the stage I information. Upon final analysis, we chose to use
pointwise and global haplotypic p values of p  .01 (empirically
evaluated) as criteria for evidence for association. Five genes
(ALAD, CDH2, EPB41L4A, PSAP, and PTGDS) showed evidence
for association at this level in single-point analyses (Table 3),
whereas associations to GLO1 and GSR remained suggestive
(.01  p  .05; Supplement 2).
Examination of two- and three-marker haplotypes supported
the single-point findings in ALAD, CDH2, and PSAP (Table 4). In
addition, DYNLL2 was implicated by the haplotype-based anal-
ysis, even though SNPs within this gene did not show evidence
for association at p  .01 in the single marker analysis. Haplo-
types in ALAD and PSAP were associated not only with social
phobia and panic disorder, respectively, but also with all anxiety
disorders combined. We did not find haplotype associations with
empirical p values of  .01 for any combination of adjacent
markers in the genes PTGDS and EPB41L4A in analysis of sliding
windows. However, when performing a combined analysis of
two non-adjacent EPB41L4A markers showing single-point asso-
ciations (rs7719346 and rs1464766, 83 kb apart), we identified
haplotypes associated with either increased or decreased risk for
social phobia. All genes with SNPs and/or haplotypes associated
to anxiety disorders with p  .01 are depicted in Figure 1.
Trend Analysis
Examination of trends in pointwise association across individ-
ual genes with a 3-df LRT revealed most noticeably that
EPB41L4A was overrepresented among the top findings, with a
clear trend toward lower representation as one descends in
ranked p values (all ranked p values  .0003; p minimized
p values  .008; Supplement 3). We further explored the
significance of this finding, focusing on the degree of overrep-
Allele Frequencies
Allelic LRT p Diagnostic GroupA1 A2
.884 .116 .008 SOCPHa
.761 .239
.333 .667 .006 SOCPHc
.488 .513
.140 .860 .008 GADa
.248 .752
.255 .745 .010 PD
.350 .651
.918 .083 .010 GADc
.849 .151
.729 .271 .004 PD
.616 .384
.615 .385 .008 PD
.502 .498
.053 .947 .010 GADc
.015 .985
tide polymorphism; LRT, likelihood-ratio test; SOCPH, social phobia; GAD,
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wesentation of this gene in the top quintile with a one-sided LRT
pall  9.46  10
6; pminimized  .002). We focused the analysis
n this way for the following reasons: 1) if a gene is influencing
he trait, one would expect overrepresentation in the top ranked
et of markers; 2) significance testing can be performed without
xtra df when the primary focus of interest is on the top decile;
nd 3) in this way, the test can be made one-sided, because a
aucity of results in this tail would not be of inferential impor-
ance. The observed deviation from the expected distribution of
anks supports the evidence for etiological involvement of
PB41L4A, with the rank-test p value remaining significant after
onferroni-correction (pall  .0001; pminimized  .028).
Linkage disequilibrium among markers might create correla-
ion in their results. However, the average pairwise marker
inkage disequilibrium in each gene is similar, and only
PB41L4A shows a clear trend in ranks. Furthermore, the
verage r2 between markers is quite low, implying that correla-
ion among marker signals would be minimal under the null
ypothesis.
iscussion
Adaptive responses related to anxiety, fear, and stress seem
volutionarily conserved in mammals, and genes influencing
nxiety-like behavior in mice can therefore be considered excel-
ent candidate genes also for human anxiety disorders (see
.g., 9). Several quantitative trait loci for anxiety-like behavior
ave been identified in mouse crosses (e.g., 25,26). Syntenic
egions in humans have been tested as candidate regions for
anic disorder (27) and personality trait behavioral inhibition
28). In this study, we tested whether variation in 13 genes
able 4. Two- and Three-Marker Haplotypes with Global p Value .01 in S
ene Markers Haplotype
LAD rs11789221 - rs8177822 - rs818708 C-A-C
C-C-C
C-C-T
rs818702 - rs11789221 - rs8177822 A-C-A
A-C-C
G-C-C
DH2 rs1041985 - rs7240351 C-A
C-G
T-G
YNLL2 rs10132 - rs9900038 - rs9902118 A-G-C
A-G-T
G-A-C
PB41L4A rs7719346 - rs1464766 A-A
A-G
G-A
G-G
SAP rs7092990 - rs4746097 C-C
C-T
T-T
rs7092990 - rs4746097 - rs11597008 C-C-C
C-C-T
C-T-T
T-T-T
Empirical p values from 10 000 permutations are shown. ANX, all studied
anic disorder; refer to Table 2 for gene names.
aDSM-IV core diagnosis.
bDSM-IV extended diagnosis.reviously shown to be differentially expressed between non-
ww.sobp.org/journalanxious and anxious inbred mouse strains predisposes humans
to anxiety disorders. Six of the genes (ALAD, CDH2, DYNLL2,
EPB41L4A, PSAP, and PTGDS) showed empirical p values of 
.01 in either single marker, haplotype, or both analyses. To our
knowledge, this is the first study showing evidence for associa-
tion between anxiety disorders and variants in these genes.
Neither have any conclusive functional connections between
them and anxiety been established so far, although they all seem
important for proper functioning of the central nervous system.
Delta-aminolevulinate dehydratase catalyzes conversion of
-aminolevulinate into porphobilinogen within the heme biosyn-
thetic pathway (29). It is markedly inhibited by lead (30), and a
functional polymorphism in ALAD might modulate the adverse
effects of lead burden on phobic anxiety symptoms (31). Our
most significant association for ALAD also is for a phobic
phenotype but not for the same polymorphism (rs1800435). This
difference might be explained by differences in study popula-
tion, cohort demography, and analyzed phenotype. We found a
rare risk haplotype (rs818702, rs11789221, and rs8177822), en-
riched among social phobia subjects. Intriguingly, the rare A
allele of rs817782 creates a putative miRNA binding site for
miR-204 and miR-211 (www.patrocles.org), within the ALAD
3’-UTR. We previously found Alad expressed at a higher level
in the hippocampus and periaqueductal grey of anxious mice
(14).
The CDH2 gene encodes a cell-cell adhesion molecule (32)
with several functions, including establishment of embryonic
left-right asymmetry (33), synaptic adhesion (34), and dendritic
spine (35) and cortical morphology (36). We have shown that
increased expression of Cdh2 in the pituitary gland correlates
Window Analysis
Haplotype Frequencies
Global p Diagnostic GroupCases Controls
.014 .002 .006 ANXa
.578 .607
.408 .391
.036 .000 .0009 SOCPHa
.848 .766
.116 .234
.333 .487 .001 SOCPHb
.317 .160
.350 .353
.131 .061 .009 GADb
.621 .717
.248 .222
.053 .197 .006 SOCPHa
.174 .124
.201 .159
.572 .521
.729 .616 .008 PD
.196 .310
.075 .074
.612 .552 .008 ANXb
.100 .116
.197 .259
.091 .073
ety disorders; SOCPH, social phobia; GAD, generalized anxiety disorder; PD,liding
anxiwith increased anxiety-related behavior in mice (14). This study
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J. Donner et al. BIOL PSYCHIATRY 2008;64:672–680 677igure 1. Genomic structure, relative single nucleotide polymorphism (SNP) positions, and linkage disequilibrium (LD) plots for the six genes showing
vidence for association. The SNP haplotype windows with global p values  .01 are indicated above the genomic structure of the gene. The shown
aplotype-based p value for EPB41L4A is from an analysis of two non-adjacent SNPs. The rs-numbers of SNPs showing p .01 in the single-point analysis are
ighlighted in green. The triangular plots represent pairwise comparisons of intermarker LD, measured in D’. The span of the coding sequence of each gene
s depicted with a green line. Figure modified from Locusview2.0 output (T. Petryshen, A. Kirby, and M. Ainscow, unpublished software).
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wmplicates the CDH2 intron 14 as a region influencing risk for
ocial phobia.
The DYNLL (dynein light chain LC8) proteins are components
f the motor protein complexes of dynein and myosin Va (37,38).
n neurons, the dynein complex is involved in axonal retrograde
ransport (39). The DYNLL2 binds multiple proteins in the brain,
ncluding synaptic scaffolding proteins and enzymes of gluta-
ate metabolism (40). Interestingly, DISC1, a susceptibility factor
or schizophrenia, schizoaffective disorder, bipolar disorder,
epression, and autism spectrum disorders (41), is also part of
he dynein complex (42). Our results suggest that haplotypes of
YNLL2, which is expressed at a higher level in the periaque-
uctal grey of anxious mice (14), modulate susceptibility to
eneralized anxiety disorder.
The functions of EPB41L4A are largely unknown, but it might
egulate interactions between the plasma membrane and the
ytoskeleton (43). The EPB41L4A is upregulated in vitro by
ctivation of 	-catenin (44). Beta-catenin and the Wnt signaling
athway have been implicated in the pathophysiology and
reatment of mood disorders, and recent characterization of
orebrain-specific conditional 	-catenin knock-out mice revealed
ome evidence for a depression-like phenotype (45). The
pb41l4a is expressed at a higher level in the pituitary gland of
nxious mice (14). In this study, we found that genetic variants
ithin EPB41L4A might influence susceptibility to several anxi-
ty disorders. Our most significant association was to a common
is¡Tyr polymorphism (rs7719346) in generalized anxiety dis-
rder.
The PSAP gene encodes a glycoprotein precursor that is
leaved into four soluble saposins A–D, which stimulate the
ydrolysis of sphingolipids (46). Unprocessed PSAP exists also as
n integral surface membrane protein in neuronal cells (47).
rosaposin has been suggested to function as a neurotrophic
actor (48,49) and to be a neural injury-repair protein (50).
onsistently, Psap knockout mice show neurodegeneration (51).
uggestive evidence for association between PSAP and schizo-
hrenia was recently reported (52). In this study, we found two
NPs upstream of PSAP associating with panic disorder, in a
egion containing putative regulatory elements (53). We previ-
usly observed increased expression of Psap in periaqueductal
rey of anxious mice (14).
Prostaglandin D2 synthase is the enzyme responsible for the
iosynthesis of brain prostaglandin D2, which functions as a
euromodulator and/or trophic factor (54) and participates in the
egulation of sleep (55). Changes in cerebrospinal fluid PTGDS
uantity have been observed in multiple sclerosis, schizophre-
ia, and Parkinson’s disease (56). Anxious mice show decreased
xpression of Ptgds in the bed nucleus of the stria terminalis and
eriaqueductal grey (14). We found here association of
s4880179 with generalized anxiety disorder.
The results of this study should be interpreted in the context
f certain limitations including: 1) limited diagnostic subgroup
ample size, 2) problems related to multiple testing correction
hen a large number of SNPs have been investigated, and 3)
ifferences between mouse and human studies. Each of these is
riefly discussed in the following text.
There is a disadvantage in studying a complex phenotype
ith a limited sample size. Nevertheless, we feel that both
ombined and separate analyses of specific anxiety disorders are
arranted, because these diseases seem to be influenced by both
hared and disorder-specific genes (6). Our restricted sample size
s exemplified by some fluctuation in p values in the analyses of
ore and extended diagnostic groups (e.g., rs7719346 and
ww.sobp.org/journalrs4880179). However, our cohort is comparatively well-charac-
terized. It is derived from a population-based study and repre-
sents the general Finnish population, which has reduced genetic
and environmental heterogeneity (17,57). Both cases and control
subjects were interviewed, and because we carefully matched
control subjects we do not consider population stratification to
be a source of false positives.
Due to the large number of SNPs studied (n  144) in several
diagnostic subgroups (n 7), we have carried out 1008 statistical
tests. Therefore, none of our results would survive correction for
multiple testing across all tests with a conventional Bonferroni-
correction. For this reason, replication in other cohorts is needed
to assess the significance of these genes to anxiety disorders in
general. Nevertheless, a potential role for particularly EPB41L4A
in susceptibility to anxiety disorders was suggested by an
analysis of trends in pointwise association between genes.
Although mice can be used to model some aspects of human
anxiety fairly well (e.g., 9), it is possible that cognitive differences
account for discrepancies between our mouse and human study,
besides the type of variation (gene expression vs. DNA polymor-
phisms) investigated. Although Glo1 and Gsr were functionally
shown to regulate anxiety in mice (14), it seems unlikely on the
basis of this study that common genetic variants within these
genes play a major role in the etiology of human anxiety
disorders. Others examining a functional Ala/Glu polymorphism
(rs2736654) within GLO1 similarly failed to establish a convinc-
ing association with panic disorder (58). However, the genes for
which no associations were discovered might nevertheless be
important modulators of anxiety, because the role of genetic
variation in their hypothetical trans-acting regulatory elements
remains to be assessed. In fact, considering that the investigated
genes were identified on the basis of differential expression, it is
appealing that two of our strongest associations, in ALAD and
PSAP, are within potential regulatory regions that might regulate
gene expression. Because functional characterization of candi-
date genes in animal models is laborious and time-consuming,
we have not shown causality for all genes studied in this work.
However, we have now potentially identified the subset of our
candidate genes that is most relevant for human anxiety disor-
ders. This information will enable us to prioritize genes for future
functional testing in mice.
In conclusion, we report here that six candidate genes first
identified as being differentially expressed between anxious and
non-anxious mouse strains are also implicated as possible sus-
ceptibility genes for human anxiety disorders. Future replication
of our results in independent study samples as well as functional
studies are needed to shed light on the role of these genes in the
regulation of normal and pathological anxiety. Nevertheless, our
results illustrate the potential utility of cross-species approaches
in the identification of susceptibility genes for human psychiatric
disorders.
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